Related Experiment Videos
Liposomes in the treatment of infections
I A Bakker-Woudenberg1, G Storm, M C Woodle
1Dept. Clinical Microbiology, Erasmus University Rotterdam, The Netherlands.
Abstract:
The use of liposomes in the treatment of severe infections is under investigation. Classical liposomes which localize in cells of the mononuclear phagocyte system (MPS) can be exploited in two ways. First for targeting of macrophage modulators such as muramyl peptides or IFN-gamma, to stimulate the cells of the MPS to maximal blood clearance capacity. This enhanced nonspecific anti-infectious resistance is important as in immunocompromised patients micro-organisms frequently appear in the blood from a local infection. Secondly, classical liposomes are successfully used as carriers of antibiotics in experimental intracellular parasitic-, viral-, fungal- or bacterial infections in MPS tissues. Based on these data extensive studies in patients with severe fungal infections have demonstrated successful treatment with liposomal or lipid-complexed amphotericin B. More recently, liposomal amphotericin B appeared to be effective in patients with drug-resistant visceral leishmaniasis. For the treatment of Mycobacterium avium complex infection in AIDS patients the efficacy of liposomal gentamicin is under investigation. With respect to infections in non-MPS tissues the applicability of Stealth liposomes characterized by long circulation half-lives is under investigation. Substantial localization of these liposomes in infected lung tissue of rats was demonstrated. Preliminary data in experimental bacterial lung infection showed superior efficacy of antibiotic encapsulated in Stealth liposomes.
Insights
Liposomes offer novel strategies for treating severe infections by targeting immune cells or delivering antibiotics. Research shows liposomal drug delivery is effective against fungal, parasitic, and bacterial infections, including drug-resistant cases.
Area of Science:
- Pharmaceutical Sciences
- Infectious Diseases
- Nanomedicine
Background:
- Liposomes are investigated for severe infection treatment.
- Classical liposomes target mononuclear phagocyte system (MPS) cells.
- Stealth liposomes offer prolonged circulation for non-MPS infections.
Purpose of the Study:
- To explore liposome applications in treating severe infections.
- To leverage liposomes for immune modulation and targeted drug delivery.
- To assess liposomal efficacy in both MPS and non-MPS infections.
Main Methods:
- Utilizing classical liposomes to deliver macrophage modulators (e.g., muramyl peptides, IFN-gamma).
- Employing liposomes as antibiotic carriers for intracellular infections within MPS tissues.
- Investigating Stealth liposomes for infections outside the MPS.
Main Results:
- Liposomal amphotericin B shows success in severe fungal infections and drug-resistant visceral leishmaniasis.
- Liposomal gentamicin efficacy is under investigation for Mycobacterium avium complex in AIDS patients.
- Stealth liposomes demonstrate localization in infected lung tissue and superior efficacy in experimental bacterial lung infections.
Conclusions:
- Liposomes are effective therapeutic agents for various severe infections.
- Liposomal drug delivery enhances treatment outcomes, particularly for resistant and intracellular pathogens.
- Further research into Stealth liposomes holds promise for treating non-MPS infections.